Skip to main content

Market Overview

Audentes Therapeutics' Strong Pipeline Merits An Outperform Rating From Cowen And Company

Share:
Audentes Therapeutics' Strong Pipeline Merits An Outperform Rating From Cowen And Company

Cowen and Company started coverage on Audentes Therapeutics Inc (NASDAQ: BOLD) with an Outperform rating, citing the strong pipeline and the bold steps taken entering into rare disease gene therapy.

Analyst Ritu Baral stated the rating was backed by pipeline assets like AT132, AT342 and AT982 and their respective values. The analyst expressed confidence in the company's move to get approval for every gene therapy candidate.

The brokerage liked the way Audentes focuses on rare monegenic diseases, since it provides tremendous opportunities in the absence of "straightforward disease-relevant biomarkers." The lead analyst thinks that the company's investment in the process of manufacturing does not pose a big risk, citing the commercial-regulatory part of the business.

Related Link: Audentes Therapeutics Initiated Overweight At Wedbush

"We think BOLD's value is driven by lead candidate AT132 for XLMTM, further bolstered by AT342 for Crigler Najjar syndrome and AT982 for Pompe disease. We expect quarterly IND submissions beginning 3Q16 for all 3 program with multiple data readouts in 2H17," the analyst said.

The brokerage expects Audentes to generate worldwide sales of $150 million from AT342, which demonstrates promise and efficacy in mouse models. Similarly, the analyst estimates $500 million worldwide sales from AT982 based on treatment cost of $1.5 million.

On the possible downside risks, Cowen cited any delay in getting clinical development and failure of AT132 could invite negative investor sentiment.

At time of writing, Audentes was up 1.55 percent on the day, trading at $14.93.

Latest Ratings for BOLD

DateFirmActionFromTo
Dec 2019Evercore ISI GroupDowngradesOutperformIn-Line
Dec 2019JP MorganDowngradesOverweightNeutral
Dec 2019Chardan CapitalDowngradesBuyNeutral

View More Analyst Ratings for BOLD

View the Latest Analyst Ratings

 

Related Articles (BOLD)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas Health Care Initiation Analyst Ratings Trading Ideas General Best of Benzinga

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com